---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000910"
form_type: "8-K"
ticker: "SBEV"
cik: "0001553788"
company_name: "SPLASH BEVERAGE GROUP, INC."
filed_at: "2026-07-06T12:46:06+00:00"
generated_at: "2026-07-06T12:50:05.560997+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Splash Beverage acquires exclusive global rights to CannEpil epilepsy therapy from Argent BioPharma

## Summary
- Exclusive global license for CannEpil, a cannabinoid-based therapy for drug-resistant epilepsy already used in Europe.
- Consideration includes $1M investment from C/M Capital, $5M debt forgiveness, and $5.5M preferred equity issuance.
- Argent BioPharma to receive 15% royalty on net revenue from worldwide sales of CannEpil.
- CannEpil has FDA pre-IND engagement and an IND number for U.S. clinical development.
- Drug-resistant epilepsy affects ~30% of epilepsy patients; therapy has EU-GMP manufacturing and European patient access.

## SEC filing metadata
- accession: 0001731122-26-000910
- form_type: 8-K
- ticker: SBEV
- cik: 0001553788
- company_name: SPLASH BEVERAGE GROUP, INC.
- filed_at: 2026-07-06T12:46:06+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553788/000173112226000910/0001731122-26-000910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553788/000173112226000910/e7759_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000910
- JSON: https://secwatch.observer/filing/0001731122-26-000910.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.